Regeneron Pharmaceuticals Inc. (REGN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

Regeneron Pharmaceuticals Inc. discovers, develops, and intends to commercialize pharmaceutical products for the treatment of medical conditions. The company focuses on three clinical development programs: VEGF Trap in oncology; VEGF Trap eye formulation in eye diseases; and IL-1 Trap in systemic inflammatory indications.

Data as of 2020-11-22
Market Cap55.353 Billion Shares Outstanding106.706 Million Avg 30-day Volume835.862 Thousand
P/E Ratio19.0 Dividend Yield EPS27.35
Price/Sales6.598 Price cash flow ratio27.6 Price free cash flow ratio35.0
Book Value94.89 Price to Tangible Book5.47 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.026202
BETA0.398637 52-week High/Low664.64 / 328.125 Stddev0.10378
View SEC Filings from REGN instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 17 25 -32.0% 10 (0.66%) 13 (0.84%) -23.08%
Funds Holding: 862 904 -4.65% 180 (11.83%) 188 (12.2%) -4.26%
13F shares: 90.643 Million 91.449 Million -0.88% 19.788 Million 20.563 Million -3.77%
% Ownership 85.1973 85.9546 -0.88% 18.5989 19.3278 -3.77%
New Positions: 96 194 -50.52% 24 49 -51.02%
Increased Positions 355 376 -5.59% 71 59 20.34%
Closed Positions 119 73 63.01% 29 18 61.11%
Reduced Positions 303 233 30.04% 63 60 5.0%
Total Calls 1.607 Million 1.71 Million -6.02% 713.8 Thousand 510.9 Thousand 39.71%
Total Puts 1.676 Million 1.67 Million 0.4% 514.9 Thousand 524.9 Thousand -1.91%
PUT/CALL Ratio 1.04 0.98 6.12% 0.72 1.03 -30.1%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

 
Regeneron Pharmaceuticals Inc. Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

WhaleWisdom Alpha

Our Other Reporting & Analysis

Funds Holding REGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding REGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

200 total shares from 16 transactions

Exercise Derivative Conversion (M)

5.2 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RYAN ARTHUR F

  • Director
 23,643 2020-12-01 11

COLES N ANTHONY

  • Director
 654 2020-11-13 2

MURPHY ANDREW J EVP RESEARCH

  • Officer
 51,378 2020-10-22 6

GOLDSTEIN JOSEPH L

  • Director
 5,643 2020-10-05 9

BROWN MICHAEL S

  • Director
 14,992 2020-09-22 6

SING GEORGE L

  • Director
 59,665 2020-08-31 9

POON CHRISTINE A

  • Director
 1,433 2020-08-28 2

LAROSA JOSEPH J EVP GENERAL COUNSEL AND SECRET

  • Officer
 14,725 2020-08-27 7

VAN PLEW DANIEL P EVP & GENERAL MGR INDUSTRIAL O

  • Officer
 21,029 2020-08-25 5

MCCOURT MARION SVP COMMERCIAL

  • Officer
 14,053 2020-08-20 2

VAGELOS P ROY

  • Director
 288,253 2020-08-11 5

LANDRY ROBERT E EVP FINANCE CFO

  • Officer
 24,175 2020-08-04 18

FENIMORE CHRISTOPHER R. VP CONTROLLER

  • Officer
 23,623 2020-07-20 6

ZOGHBI HUDA Y

  • Director
 643 2020-07-07 4

BASSLER BONNIE L

  • Director
 643 2020-06-19 3

SANOFI

279,766 2020-06-09 3

SCHLEIFER LEONARD S PRESIDENT & CEO

  • Officer
  • Director
 580,347 2020-05-11 2

STAHL NEIL EVP RESEARCH AND DEVELOPMENT

  • Officer
 38,674 2020-05-08 6

TESSIER-LAVIGNE MARC

  • Director
 1,830 2020-05-06 3

YANCOPOULOS GEORGE PRESIDENT AND CHIEF SCIENTIFIC

  • Officer
  • Director
 557,465 2020-03-09 4

BAKER CHARLES A

  • Director
 0 2018-01-02 0

TERIFAY ROBERT J EVP COMMERCIAL

  • Officer
 0 2017-12-12 0

ABERMAN MICHAEL S SVP STRATEGY INVESTOR RELATION

  • Officer
 16,946 2017-06-21 0

POWCHIK PETER SVP CLINICAL DEVELOPMENT & REG

  • Officer
 32,306 2016-12-16 0

MCCORKLE DOUGLAS S VP CONTROLLER AND ASST TREASUR

  • Officer
 10,995 2015-12-29 0

GILMAN ALFRED G

  • Director
 8,912 2015-08-06 0

INGRAM ROBERT ALEXANDER

  • Director
 1,500 2015-05-22 0

GOLDBERG MURRAY A SVP ADMINISTRATION & ASST SECR

  • Officer
 70,836 2014-12-16 0

SHOOTER ERIC M

  • Director
 5,000 2014-02-12 0

ROBERTS WILLIAM VP REG DEV & MED SAFETY

  • Officer
 53,879 2013-09-18 0

SANOFI-AVENTIS

SANOFI-AVENTIS AMERIQUE DU NORD S.N.C.

  • 10% Owner
 15,816,953 2010-10-13 0

KOLINSKI STUART SVP GENERAL COUNSEL AND SECRET

  • Officer
 20,039 2010-06-03 0

DWORKIN PETER VP INVESTOR RELATIONS & COMMUN

  • Officer
 0 2009-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 10 $523.32 d 23,646 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 27 $520.58 d 23,680 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 11 $517.63 d 23,726 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 14 $522.45 d 23,656 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 13 $519.60 d 23,707 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 4 $516.37 d 23,737 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 3 $524.31 d 23,643 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 10 $521.50 d 23,670 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 6 $518.55 d 23,720 direct yes

RYAN ARTHUR F - Director

2020-12-02 16:09:06 -0500 2020-12-01 S 2 $515.64 d 23,741 direct yes

COLES N ANTHONY - Director

2020-11-13 17:57:52 -0500 2020-11-13 M 11 d 13,039 direct

COLES N ANTHONY - Director

2020-11-13 17:57:52 -0500 2020-11-13 M 11 $345.47 a 654 direct -3.7798 -6.3795 0.0 1 -7.9708 4

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 20 $552.39 d 23,753 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 10 $545.59 d 23,813 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 20 $548.58 d 23,773 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 20 $544.54 d 23,823 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 10 $556.02 d 23,743 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

RYAN ARTHUR F - Director

2020-11-03 17:22:58 -0500 2020-11-02 S 20 $546.40 d 23,793 direct yes 0.2844 -3.3059 0.2844 2 -4.7553 5

MURPHY ANDREW J - Officer EVP RESEARCH

2020-10-23 16:02:06 -0400 2020-10-22 M 1,921 $52.03 a 43,872 direct -0.5497 -6.3441 0.0 1 -7.2011 5

MURPHY ANDREW J - Officer EVP RESEARCH

2020-10-23 16:02:06 -0400 2020-10-22 M 3,264 d 0 direct

MURPHY ANDREW J - Officer EVP RESEARCH

2020-10-23 16:02:06 -0400 2020-10-22 M 3,264 $30.63 a 47,136 direct -0.5497 -6.3441 0.0 1 -7.2011 5

MURPHY ANDREW J - Officer EVP RESEARCH

2020-10-23 16:02:06 -0400 2020-10-22 M 1,921 d 0 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments